Beverly, MA, United States of America

Aleksei Fomenkov

This inventor holds 1 USPTO granted patent. Top assignee: New England Biolabs, Inc.. Active years: 1996.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Aleksei Fomenkov. Retrieved from https://idiyas.com/inventor/aleksei-fomenkov

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 30(Granted Patents)


Company Filing History:


Years Active: 1996

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Aleksei Fomenkov, Inventor in Beverly, Massachusetts

Introduction

Aleksei Fomenkov is an inventor associated with New England Biolabs, Inc., in Beverly, Massachusetts. His patent work concerns methods for cloning nuclease genes in *E. coli*.

Latest Patents

Fomenkov is associated with 1 patent, titled “Method for Direct Cloning of Nuclease Genes in *E. coli*.” The invention describes a method for directly cloning nuclease genes, including restriction endonuclease genes, in *E. coli*. It also provides a strain designed to facilitate the method’s application. The disclosed approach was used to clone multiple genes coding for endonucleases.

Career Highlights

Fomenkov’s patent reflects work in molecular biology and genetic engineering, particularly the cloning of genes that encode nucleases. His affiliation with New England Biolabs connects this work to the company’s focus on life-science research tools and technologies.

Collaborations

Fomenkov’s listed coworkers include Deborah K. Dila and Elisabeth A. Raleigh.

Conclusion

Aleksei Fomenkov’s patent documents a method and supporting strain for cloning nuclease genes in *E. coli*, highlighting his contribution to biotechnology research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…